AGuIX nanoparticle-nanobody bioconjugates to target immune checkpoint receptors-Reference-Cited by-同舟云学术

AGuIX nanoparticle-nanobody bioconjugates to target immune checkpoint receptors

Published:2024 Issue:5 Volume:16 Page:2347-2360
ISSN:2040-3364
Container-title:Nanoscale
language:en
Short-container-title:Nanoscale

Author:

Carmès Léna¹²^ORCID,Bort Guillaume¹³⁴^ORCID,Lux François¹⁵^ORCID,Seban Léa⁶^ORCID,Rocchi Paul¹²,Muradova Zeinaf⁶,Hagège Agnès⁷^ORCID,Heinrich-Balard Laurence⁸,Delolme Frédéric⁹,Gueguen-Chaignon Virginie⁹,Truillet Charles¹⁰^ORCID,Crowley Stephanie¹¹,Bello Elisa¹¹,Doussineau Tristan²,Dougan Michael¹¹,Tillement Olivier¹,Schoenfeld Jonathan D.⁶,Brown Needa⁶¹²,Berbeco Ross⁶

Affiliation:

1. Institut Lumière-Matière, UMR 5306, Université Lyon1-CNRS, Université de Lyon, Villeurbanne Cedex 69100, France

2. NH TherAguix SA, Meylan 38240, France

3. Institut Curie, PSL Research University, CNRS, UMR9187, INSERM, U1196, Chemistry and Modeling for the Biology of Cancer, F-91400, Orsay, France

4. Université Paris-Saclay, CNRS, UMR9187, INSERM, U1196, Chemistry and Modeling for the Biology of Cancer, F-91400, Orsay, France

5. Institut Universitaire de France (IUF), Paris, France

6. Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, and Harvard Medical School, Boston 02115, USA

7. Université de Lyon, CNRS, Université Claude Bernard Lyon 1, Institut des Sciences Analytiques, UMR 5280, 69100, Villeurbanne, France

8. Université Lyon 1, CNRS, MATEIS, UMR5510, Univ Lyon, Université Claude Bernard Lyon 1, Villeurbanne 69100, France

9. Université Lyon, Université Claude Bernard Lyon 1, ENS de Lyon, CNRS UAR3444, Inserm US8, SFR Biosciences, F-69007 Lyon, France

10. Université Paris-Saclay, CEA, CNRS, Inserm, BioMaps, SHFJ, Orsay 91400, France

11. Division of Gastroenterology, Massachusetts General Hospital, Boston, MA, 02114, USA

12. Department of Physics, Northeastern University, Boston 02115, USA

Abstract

Comparison of click chemistry and sortagging grafting strategies for functionalizing AGuIX nanoparticles with nanobodies to develop a tri-functional technology combining MRI imaging, radiotherapy, and immunotherapy by inhibiting immune checkpoints.

Funder

Centre National de la Recherche Scientifique

ViewRay

Publisher

Royal Society of Chemistry (RSC)

Subject

General Materials Science

Link

http://pubs.rsc.org/en/content/articlepdf/2024/NR/D3NR04777F

Reference79 articles.

1. Theranostic AGuIX nanoparticles as radiosensitizer: A phase I, dose-escalation study in patients with multiple brain metastases (NANO-RAD trial)

2. Phase I/II study testing the combination of AGuIX nanoparticles with radiochemotherapy and concomitant temozolomide in patients with newly diagnosed glioblastoma (NANO-GBM trial protocol)

3. Gadolinium-based nanoparticles for theranostic MRI-radiosensitization

4. Toward Clinical Transfer of Tumor‐Targeted Ultrasmall Inorganic Nanoparticles